CGRP Antibodies as Prophylaxis in Migraine

Area of Science:

• Neurology
• Pharmacology
• Immunology

Background:

• Migraine treatment has historically relied on non-specific therapies.
• The trigeminal pain system plays a crucial role in migraine pathophysiology.
• Calcitonin gene-related peptide (CGRP) is a key mediator in migraine.
• Existing migraine drugs have limitations in efficacy and side effect profiles.

Purpose of the Study:

• To review the development and clinical application of monoclonal antibodies targeting CGRP or its receptor for migraine prophylaxis.
• To highlight the advancements these therapies bring compared to existing treatments.
• To discuss the impact of CGRP-targeted therapies on the management of migraine.

Main Methods:

• Review of clinical trial data and regulatory approvals for CGRP-targeting monoclonal antibodies.
• Analysis of the mechanism of action of antibodies against CGRP and its receptor components (CLR + RAMP1).
• Comparison of efficacy and safety profiles with established migraine prophylactic medications.

Main Results:

• Monoclonal antibodies targeting CGRP or its receptor demonstrate significant improvements in migraine prophylaxis.
• Erenumab, targeting the CGRP receptor, received FDA and EMA approval in 2018.
• Fremanezumab and galcanezumab, targeting the CGRP ligand, were approved by the FDA in late 2018.
• These antibodies represent a novel class of migraine treatments focused on the trigeminal pain pathway.

Conclusions:

• CGRP-targeting monoclonal antibodies offer a new and effective strategy for migraine prevention.
• These therapies provide a targeted approach to the trigeminal pain system, improving patient outcomes.
• The availability of these drugs marks a significant milestone in migraine management, moving from bench to bedside.